Cwm LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 83,213 shares of the biopharmaceutical company’s stock after acquiring an additional 2,009 shares during the quarter. Cwm LLC’s holdings in Gilead Sciences were worth $5,961,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. boosted its position in shares of Gilead Sciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. FMR LLC boosted its position in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares during the period. Northern Trust Corp boosted its position in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Gilead Sciences by 1.0% in the 2nd quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock valued at $1,027,436,000 after purchasing an additional 136,884 shares during the period. 75.71% of the stock is owned by institutional investors and hedge funds.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the completion of the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the transaction, the insider now directly owns 3,046,766 shares of the company’s stock, valued at $224,302,912.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 418,333 shares of company stock valued at $32,742,108. Company insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of research analyst reports. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and decreased their target price for the company from $88.80 to $76.00 in a research report on Tuesday, January 30th. BMO Capital Markets upped their target price on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research report on Thursday, February 8th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. Finally, Credit Suisse Group cut Gilead Sciences from an “outperform” rating to a “neutral” rating and upped their target price for the company from $74.35 to $80.00 in a research report on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $87.04.
Gilead Sciences, Inc. (GILD) opened at $80.70 on Monday. The stock has a market capitalization of $105,415.91, a P/E ratio of 9.45, a PEG ratio of -1.85 and a beta of 1.22. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.70 EPS. research analysts anticipate that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.83%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 59.77%.
TRADEMARK VIOLATION WARNING: “Cwm LLC Has $5.96 Million Stake in Gilead Sciences, Inc. (GILD)” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/02/19/cwm-llc-has-5-96-million-stake-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.